Notes: BUSI 100 Day 4
Key Concept: Listen to Understand vs Listen to Reply
The speaker cites a line from Stephen Covey’s The 7 Habits of Highly Effective People: “Most people don't listen to intent to understand. They listen to intent to reply.”
Emphasizes the habit of asking for deeper explanations to truly understand another’s perspective: "Explain that to me a little bit deeper. Help me understand that I don't understand."
The point is that admitting we don’t know everything is difficult; people often cling to half-formed thoughts and reply instead of seeking genuine understanding.
Case Study: Daraprim Price Hike by Martin Shkreli (Turing Pharmaceuticals) – Facts and Controversies
Context: Discussion centered on the price increase of the life-saving drug Daraprim.
Price change (as described in the transcript):
From per pill to per pill; the transcript notes a dramatic, overnight jump and later mentions a “55 time price increase.”
In the math sense, increase factor ≈ , i.e., about a 55x rise. The transcript contains a garbled reference ("to $7.50"); context indicates the intended figure is a 750 per-pill price, yielding ~55x growth.
Scope of impact: The drug is used to treat toxoplasmosis; the transcript notes it is not a widely used drug but is important for certain patients (the exact patient count is garbled in the transcript; it mentions a small number of patients and frames the drug as life-saving for those who need it).
Immediate corporate actions claimed to accompany the price increase:
Lower price for hospital customers: a smaller bottle is being released to make hospital handling easier; argument presented is that hospitals benefit from lower unit consumption or easier administration.
Closed distribution system justification: the company argues that many expensive drugs use closed distribution to manage complex reimbursement and to avoid pharmacy-level dispensing; claimed aim is to help patients and manage reimbursement logistics.
Core arguments used by Martin Shkreli (as presented in the transcript):
Fiduciary duty: Under Delaware law, corporations are legally required to maximize shareholder value; Shkreli frames his duty as maximizing shareholder value even when it conflicts with patient access, stating that “our duty is to our shareholders.”
Capitalism and profitability: He describes capitalism as the framework in which companies raise funds (e.g., a large Series A) and must maximize profits; profits are used to fund R&D and company growth, not to endow libraries or charitable causes.
Rationale for price levels: He argues that high prices support continued investment in drug development and the broader ecosystem (R&D, future drugs) and that the money is used to fund further innovation rather than being wasted.
Investor expectations: He notes that investors expect high returns (he cites raising $100 million quickly for a large drug venture) and that this expectation drives pricing and strategy.
Key legal and ethical tension highlighted in the discussion:
Fiduciary duty vs societal duty to patients: The tension between maximizing shareholder value and ensuring patient access to life-saving medications.
The idea that the system (laws, market incentives) constrains or enables pricing behavior; debate over whether the system should be reformed.
Specific talking points from the interview excerpts:
Two reasons given for not lowering the price publicly: (1) hospital customers; (2) fiduciary duty to shareholders.
Assertion that under the current system, profits enable R&D, which should lead to long-term benefits for patients (e.g., future treatments for diseases lacking investment).
Claim that corporate reputation matters but that immediate profit maximization can supersede short-term reputational concerns.
Discussion of whether drugs should be priced via closed distribution to manage reimbursement and to prevent pharmacists from discounting the price at the point of sale.
Notable counterpoints and critical viewpoints raised in the session:
Critics question whether price increases of life-saving drugs are morally justifiable when patient populations are small but highly affected.
The Robin Hood framing (stealing from insurers to fund R&D) is debated as either a clever justification or a misrepresentation of the ethical landscape.
The legal vs ethical distinction is foregrounded: while CEO actions may be legally protected or defensible within fiduciary duty, they can be ethically controversial and socially harmful.
Consequences discussed in the transcript:
Public debate about pricing in the pharmaceutical industry and the need for policy reform.
The possibility of board turnover or regulatory scrutiny if a price strategy damages shareholder value or public trust.
The point that the market and the law shape, but do not strictly dictate, a CEO’s decisions.
Philosophical and Ethical Debates Highlighted in the Discussion
Maximizing profits vs serving patients:
The speaker notes that prices are often framed as incentives for innovation (R&D funding), but high prices can limit patient access.
Ethical question: Is it permissible to prioritize shareholder returns if it enables long-term innovation that could help more patients later?
The role of reputation:
Corporate reputation is discussed as a factor that can influence long-term earnings and social legitimacy.
Proponents argue reputation can be sacrificed for immediate profits; opponents warn of long-term costs.
Systemic critique vs individual culpability:
Some participants argue the problem lies in the broader system’s incentives and regulatory environment, not solely the CEO’s actions.
Others focus on individual accountability (the CEO’s decisions and actions like price-setting and investor relations) as the locus of responsibility.
The moral weight of fiduciary duty:
Fiduciary duty to shareholders is presented as a legal obligation, but critics question whether it should legally trump the duty to patients or society at large.
Open vs closed pricing and distribution:
The transcript discusses closed distribution as a mechanism to manage pricing and payer interactions, with implications for patient access and market transparency.
Core Financial and Investment Concepts Encountered
Fiduciary duty and shareholder maximization
Quote from the interview: “Under Delaware law, companies are, by law, required to maximize opportunities for shareholders.”
The duty is framed as a legal obligation that can guide executive decision-making, including pricing strategies.
The role of investors and capital markets
The speaker notes that investors expect returns, and that a CEO’s ability to raise large sums quickly (e.g., a $100,000,000 Series A) supports the claim that high returns are an investor expectation.
“My investors know what I do with that money and multiply for them.”
Reinvestment in R&D as a strategic justification
The belief that profits fund R&D, leading to future drugs that can treat diseases with little prior investment (e.g., toxoplasmosis reference).
The concept of “financial toxicity” and distribution strategy
The closed distribution argument is tied to managing the financial and reimbursement complexities that accompany expensive drugs.
Real-world pricing ethics in a capitalist system
The dialogue frames a classic debate: can profits and patient welfare be reconciled, or are they inherently at odds?
Practical Exercise Shown: Yahoo Finance Holders Analysis
Objective: Understand ownership structure using the Yahoo Finance “Holders” tab
Materials used in class:
A set of 50 different pieces of paper, each with a ticker for one of 10 companies from the S&P 500 (to simulate a cross-section of large-cap equities).
Procedure (as described in the transcript):
From the group sheet, select a ticker (e.g., ANZ for Amazon in the example).
Enter the ticker into the search box and view the stock page; observe current price data (price movement), though the exercise emphasizes ownership, not price.
Navigate to the tab labeled “Papers” (as a stand-in for the Holders tab in the transcript’s language).
Open the Holders section to extract two key percentages:
Insiders: the percentage of shares held by company insiders (management and board of directors).
Institutions: the percentage of shares held by institutional investors (e.g., pension funds, mutual funds).
Example given in the transcript (Amazon):
Insiders hold 8.4 ext{%} of shares.
Institutions hold 66.3 ext{%} of shares.
Conceptual definitions:
Insiders: includes management and board of directors with access to non-public information and potential influence over corporate decisions.
Institutions: large, often long-term investors (e.g., Fidelity, Goldman Sachs, pension funds) managing the retirement savings of individuals and contributing significantly to liquidity and price stability.
Real-world context for the exercise:
Institutions often hold a majority stake in large-cap firms, shaping governance through voting power and board nominations.
The exercise helps students understand how ownership structure can influence corporate behavior and governance outcomes.
Classroom execution notes:
One student per group should go to the Holders tab and record the two key percentages for the chosen ticker.
Groups should compare 10 different companies to gauge typical insider vs institutional ownership patterns across large-cap stocks.
Additional contextual notes from the lecture:
The instructor uses Amazon as an example to illustrate the insider and institutional ownership split.
Fidelity and other retirement-account providers are cited as examples of institutions that invest on behalf of individuals.
Key Terms and Concepts to Know for the Exam
Fiduciary duty: The obligation to act in the best financial interest of the shareholders in general, defined in part by corporate law (e.g., Delaware law cited in the transcript).
Closed distribution system: A distribution model used for certain expensive drugs to manage reimbursement and dispensing, often criticized as a barrier to access.
Reimbursement process: The complex mechanism by which payers (e.g., insurers, hospitals) cover drug costs; this can influence pricing strategies.
R&D funding via profits: The argument that profits from drug sales fund research and development for future therapies.
Market-based incentives vs ethical obligations: The tension between profit maximization and patient welfare.
Insider vs institutional ownership: The two primary categories of large holders in public companies; insiders are management/board, institutions are funds and large investors.
The role of reputation in business strategy: How public image can affect long-term earnings and stakeholder trust.
Ethical and legal accountability: The distinction between what is legal under fiduciary duty and what is ethically defensible in terms of patient welfare.
Formulas, Numerical References, and Equations (LaTeX)
Price increase factor (Daraprim case):
Note: Transcript contains a garbled reference to "$7.50"; the intended discussion concerns a roughly 55x price rise to $750 per pill.
Financing milestone mentioned:
raised in a two-week period for a Series A round (large seed/early-stage capital raise).
Ownership example (Amazon, as used in class):
Insiders: 8.4 ext{%}
Institutions: 66.3 ext{%}
Investment return commentary (conceptual, not a strict formula):
Mentions target returns like 6% in examples, and the notion of long-run multipliers such as 10x, 20x, or 50x on R&D investments, illustrating the math-minded framing of investment in drug development.
Discussion Prompts and Exam-Style Questions (derived from the transcript)
What is fiduciary duty, and how does it interact with a company’s obligation to patients in high-priced drug scenarios?
Is it ethically defensible to price a life-saving drug at a level that maximizes shareholder value if it restricts access for some patients?
How does the closed-distribution approach affect patient access, pharmaceutical pricing, and overall healthcare costs?
In what ways can corporate reputation influence long-term earnings, and is it a sufficient counterweight to short-term profit maximization?
Discuss the argument that profits fund R&D. What assumptions underlie this claim, and what evidence would you require to evaluate it critically?
How do insiders’ and institutions’ ownership structures influence corporate governance and strategic decision-making?
If you were on a board, what governance mechanisms would you advocate to balance patient welfare with shareholder value?
What reforms (policy, regulatory, or market-based) could address concerns about pricing in the pharmaceutical industry without stifling innovation?
Quick Synthesis and Takeaways
The transcript frames a central ethical-economic tension: profit maximization vs patient access in the pricing of essential medicines.
It uses a real-world case (Shkreli and Daraprim) to illustrate how fiduciary duty, market incentives, and corporate governance interact in high-stakes pharmaceutical pricing.
The classroom activity on stock ownership (insiders vs institutions) is intended to build financial literacy about who controls corporate outcomes and how that shapes decisions.
Across the discussion, the argument that “profit drives innovation” is juxtaposed with concerns about social responsibility and the moral implications of price gouging.